Consensus ESG Ratings
Member Sign In
ESG News For Beigene Ltd (ADR)
These sites contributed news to this page:
-
BeiGene Demonstrates Global Progress in 2023 Responsible Business & Sustainability Report
Newly released report details Company’s achievements and plans for sustainable growth
-
BeiGene Receives FDA Approval for TEVIMBRA® for the Treatment of Advanced or Metastatic Esophageal Squamous Cell Carcinoma After Prior Chemotherapy
Results from the global, Phase 3 RATIONALE 302 trial showed TEVIMBRA prolonged the survival of patients who received prior systemic treatment compared to chemotherapy
Approval represents the first indication in the U.S. for TEVIMBRA
-
First Doses of BRUKINSA® provided to Patients with Chronic Lymphocytic Leukemia in Low- and Middle-Income Countries Under Collaboration of The Max Foundation, BeiGene, and the BeiGene Foundation
Armenia and Nepal are the first of 29 countries to receive BRUKINSA
-
Corporate Social Responsibility Related News Releases and Story Ideas for Reporters, Bloggers and Media Outlets
Recap of CSR stories on Business Wire -
BeiGene Announces Goals Focused on Sustainable Growth and Workforce Diversity in New ESG Report
Newly Released Report Details Company’s Progress and Plans for Growing Responsibly